Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (innate lymphoid cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: namilumab, gimsilumab, otilimab +3 | 0.81 |
| trials ClinicalTrials.gov | 9 Parkinson's trials, 1 stopped | 0.91 |
| literature PubMed | 2 Parkinson's papers of 777 | 0.85 |
| pathways Reactome | 5 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 5426
Sealed predictions
- CSF2 in dopamine neurons, braakn/a → n/areceipt 5432
Swarm cases
receipt 5432: CSF2 in dopamine neurons, braak
- cell type
- CSF2 is not measured in dopamine neurons; looking elsewhere.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CSF2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts